TRI
TRIVARX FPO [TRI]
Healthcare · ASX Small Cap
$0.0250 -10.7%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +4First seen: 2026-02-25
Score Breakdown
Technical63
Catalyst50
Sentiment50
Fundamental54
Momentum56
Risk Gate45
Active Signals
Bullish Signals
- Price above MAs (uptrend)
- Strong 5-day momentum (+19.0%)
- Strong cash runway (13 quarters)
- 4C filed 2026-01-29
- Revenue in sharp decline (-100%)
- Small-cap ($20-100M)
- Positive 12-1 momentum (+31%)
- Pre-revenue company — Altman Z-Score not applicable
- Low-priced stock risk ($0.028)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- Piotroski F-Score weak (3/9)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Revenue momentum declining (-100%)
Recent Catalysts
NONE Appendix 4D & Half-Year Financial Report to 31 December 2025
NONE Final Director's Interest Notice - John Mathias
LOW December 2025 Quarterly Activities Report and Appendix 4C
Recent ASX Announcements
| 2026-02-24 | Appendix 4D & Half-Year Financial Report to 31 December 2025 PRICE SENSITIVE |
| 2026-01-29 | December 2025 Quarterly Activities Report and Appendix 4C PRICE SENSITIVE |
| 2026-01-01 | Final Director's Interest Notice - John Mathias |
Key Metrics
$32.3M
Market Cap
2.0M
Avg Volume
1.4x
Vol Ratio
$0.01 — $0.04
52-Week Range
0.0%
Short Interest
13 qtrs
Cash Runway
-12.1%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 78% |
| L | Leader vs Laggard | pass | RS: 4 |
| I | Institutional Sponsorship | weak | Inst: 7% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #42 of 119 · Sector avg: 51
View all Healthcare signals →